Sold as Mintezol. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Thiabendazole (sold as Mintezol), first approved Apr 7, 1967, with 0 new uses approved and 0 published complete response letters.
| Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic SyndromeMetabolic Syndrome · Consorci Sanitari de Terrassa | Not applicable | Recruiting | Jun 27, 2025 |
| Immersive Virtual Reality Techniques on the Effects on Cognition in People With CancerCancer, Cognitive Impairment · Consorci Sanitari de Terrassa | Not applicable | Recruiting | Jun 18, 2023 |
| Apr 7, 1967 | MintezolNDA 16096 · New molecular entity | Merck Sharp Dohme | 25 | Discontinued |
| Apr 21, 1967 | MintezolNDA 16097 · New dosage form | Merck Sharp Dohme | 16 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
